Norges Bank’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-279,000
| Closed | -$421K | – | 2055 |
|
|
2023
Q1 | $421K | Hold |
279,000
| – | – | ﹤0.01% | 2057 |
|
|
2022
Q4 | $698K | Buy |
+279,000
| New | +$698K | ﹤0.01% | 2080 |
|
|
2022
Q3 | – | Sell |
-887,122
| Closed | -$2.48M | – | 2106 |
|
|
2022
Q2 | $2.48M | Buy |
887,122
+63,800
| +8% | +$178K | ﹤0.01% | 1876 |
|
|
2022
Q1 | $4.71M | Buy |
823,322
+14,362
| +2% | +$82.2K | ﹤0.01% | 1882 |
|
|
2021
Q4 | $7.39M | Buy |
808,960
+95
| +0% | +$867 | ﹤0.01% | 1836 |
|
|
2021
Q3 | $8.65M | Buy |
808,865
+209,000
| +35% | +$2.23M | ﹤0.01% | 1808 |
|
|
2021
Q2 | $9.31M | Buy |
599,865
+746
| +0.1% | +$11.6K | ﹤0.01% | 1802 |
|
|
2021
Q1 | $9.71M | Sell |
599,119
-567,486
| -49% | -$9.2M | ﹤0.01% | 1791 |
|
|
2020
Q4 | $24.7M | Sell |
1,166,605
-213,666
| -15% | -$4.52M | 0.01% | 1439 |
|
|
2020
Q3 | $20.5M | Sell |
1,380,271
-104,144
| -7% | -$1.54M | 0.01% | 1408 |
|
|
2020
Q2 | $21.8M | Buy |
1,484,415
+354,417
| +31% | +$5.21M | 0.01% | 1377 |
|
|
2020
Q1 | $13.3M | Buy |
1,129,998
+134,918
| +14% | +$1.58M | ﹤0.01% | 1488 |
|
|
2019
Q4 | $23.4M | Buy |
995,080
+193,289
| +24% | +$4.54M | 0.01% | 1443 |
|
|
2019
Q3 | $14.8M | Buy |
801,791
+76,268
| +11% | +$1.41M | ﹤0.01% | 1628 |
|
|
2019
Q2 | $13.5M | Buy |
725,523
+78,383
| +12% | +$1.46M | ﹤0.01% | 1695 |
|
|
2019
Q1 | $15.8M | Buy |
647,140
+119,789
| +23% | +$2.93M | 0.01% | 1632 |
|
|
2018
Q4 | $13.7M | Buy |
527,351
+70,912
| +16% | +$1.84M | 0.01% | 1603 |
|
|
2018
Q3 | $14.4M | Buy |
456,439
+406,439
| +813% | +$12.9M | ﹤0.01% | 1687 |
|
|
2018
Q2 | $1.94M | Buy |
+50,000
| New | +$1.94M | ﹤0.01% | 2027 |
|
|
2017
Q4 | – | Sell |
-20,000
| Closed | -$323K | – | 2126 |
|
|
2017
Q3 | $323K | Hold |
20,000
| – | – | ﹤0.01% | 2109 |
|
|
2017
Q2 | $277K | Hold |
20,000
| – | – | ﹤0.01% | 2106 |
|
|
2017
Q1 | $300K | Buy |
+20,000
| New | +$300K | ﹤0.01% | 2125 |
|